Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)
China flag China · Delayed Price · Currency is CNY
25.54
+0.61 (2.45%)
Sep 30, 2026, 3:04 PM CST

SHE:300683 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
197.83648.33419.15510.22748.48184.05
Short-Term Investments
429.152.234.560.3142.75491.39
Trading Asset Securities
196.94170.63449.69578.71144.04514.4
Cash & Short-Term Investments
823.92821.19873.41,0891,0351,190
Cash Growth
11.54%-5.98%-19.81%5.21%-12.99%18.99%
Accounts Receivable
291.64298.58300.78254.58233.21264.48
Other Receivables
0.490.1100-3.18
Receivables
292.13298.69300.78254.58233.21270.15
Inventory
84.5782.94108.98117.41120.1871.65
Other Current Assets
30.3727.0523.1826.9855.4750.88
Total Current Assets
1,2311,2301,3061,4881,4441,583
Property, Plant & Equipment
637.61658.14729.69734.56654.23519.63
Long-Term Investments
40.1442.8516.5827.0888.8965.29
Goodwill
178.59178.59263.59263.59302.15316.17
Other Intangible Assets
216.69229.09253.44276.8890.3790
Long-Term Deferred Tax Assets
127.04120.52119.94109.4780.5971.64
Long-Term Deferred Charges
3234.5134.4931.962.622.39
Other Long-Term Assets
8.282.97212.5739.5143.8749.87
Total Assets
2,4712,5772,9372,9712,7072,698

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
34.6733.1364.3552.0858.0551.72
Accrued Expenses
104.316379.1159.8646.5146.42
Short-Term Debt
7.067.067.227.3230.0333.04
Current Portion of Long-Term Debt
20.0621.3714.8314.667.313.21
Current Portion of Leases
0.430.935.124.80.71.87
Current Income Taxes Payable
2.172.173.872.842.464.52
Current Unearned Revenue
47.0253.7777.5411697.9966.38
Other Current Liabilities
66.32127.41111.2188.5841.6842.09
Total Current Liabilities
282.04308.85363.26346.15284.73249.25
Long-Term Debt
--11.5226.3240.9248.17
Long-Term Leases
3.393.95.3610.42.593.64
Long-Term Unearned Revenue
85.4183.0484.2530.4727.922.59
Long-Term Deferred Tax Liabilities
10.4611.3514.7416.4813.117.25
Other Long-Term Liabilities
--45.9245.922.4523.56
Total Liabilities
381.3407.14525.05475.73371.7354.46

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
130.89130.89130.89130.89122.1122.1
Additional Paid-In Capital
1,8371,8371,8371,8371,5571,557
Retained Earnings
114192.71423.98510.34631.16645.19
Total Common Equity
2,0822,1612,3922,4782,3102,324
Minority Interest
7.698.8719.817.3724.7918.65
Shareholders' Equity
2,0902,1692,4122,4962,3352,343
Total Liabilities & Equity
2,4712,5772,9372,9712,7072,698

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
30.9433.2644.0563.581.5589.92
Net Cash (Debt)
792.98787.93829.351,026953.731,100
Net Cash Growth
13.21%-4.99%-19.14%7.55%-13.29%10.72%
Net Cash Per Share
6.066.036.347.907.4810.34
Filing Date Shares Outstanding
130.89130.89130.89130.89122.1122.1
Total Common Shares Outstanding
130.89130.89130.89130.89122.1122.1
Working Capital
948.94921.02943.071,1421,1591,333
Book Value Per Share
15.9116.5118.2718.9318.9219.04
Tangible Book Value
1,6871,7531,8751,9381,9181,918
Tangible Book Value Per Share
12.8913.3914.3214.8015.7115.71
Buildings
503.22503.22500.14500.38398.72350.14
Machinery
523.84521.43528.75480.61339.05291.83
Construction In Progress
11.837.3611.022.99120.9934.27